Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D9HA
|
|||
| Former ID |
DND000091
|
|||
| Drug Name |
PF-04634817
|
|||
| Indication | Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Phase 2 | [1] | |
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H36F3N5O3
|
|||
| Canonical SMILES |
CC(C)C1(CCC(C1)NC2CCOCC2OC)C(=O)N3CC4CC3CN4C5=NC=NC(=C5)C(F)(F)F
|
|||
| InChI |
1S/C25H36F3N5O3/c1-15(2)24(6-4-16(10-24)31-19-5-7-36-13-20(19)35-3)23(34)33-12-17-8-18(33)11-32(17)22-9-21(25(26,27)28)29-14-30-22/h9,14-20,31H,4-8,10-13H2,1-3H3/t16-,17+,18+,19+,20-,24+/m1/s1
|
|||
| InChIKey |
MCRWZBYTLVCCJJ-DKALBXGISA-N
|
|||
| CAS Number |
CAS 1228111-63-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01712061) A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.